Company intelligence / Profile preview
SanegeneBio
Boston, Massachusetts, United Statessanegenebio.com ↗
- Ownership
- Private
- Employees
- ~101
- Development stage
- Phase 2
01
Overview
The company has three clinical-stage siRNA assets targeting cardiovascular and metabolic diseases (PCSK9 and AGT) and immune diseases (Complement C3), as well as two IND-stage assets and several others in preclinical development.
- Therapeutic areas
- ImmunologyCardiovascularNeurologyMetabolic Disorders
- Modalities
- RNA interference (RNAi) therapeuticssiRNA
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →03
Partnerships
Innovent
Beyond the preview
Go deeper on SanegeneBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SanegeneBio.